Overview

Adagrasib in Combination With Nab-Sirolimus in Patients Wtih Advanced Solid Tumors and Non-Small Cell Lung Cancer Wtih a KRAS G12C Mutation (KRYSTAL -19)

Status:
Not yet recruiting

Trial end date:
2026-06-30

Target enrollment:

Participant gender:

Summary

This study will evaluate the safety, MTD and/or RP2D, PK, and clinical activity of the combination of adagrasib with nab-sirolimus in patients with advanced solid tumors/NSCLC with a KRAS G12C mutation.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Mirati Therapeutics Inc.

Collaborator:

Aadi Bioscience, Inc.

Treatments:

Adagrasib
Sirolimus